Cellular Adaptation and Resistance to Ubiquitin Proteasome Drugs
While ubiquitin proteasome–targeting drugs are highly effective in disrupting diseased cells, some cells develop adaptive responses over time. These adaptations are not driven by external economic or competitive factors but arise from intrinsic cellular survival mechanisms. Understanding these biological responses is essential for improving long-term therapeutic outcomes.
One major adaptive mechanism involves changes in proteasome composition. Cells may alter the structure or activity of proteasome subunits to reduce drug sensitivity. This allows partial restoration of protein degradation despite continued drug exposure. In parallel, stress-response pathways become more active, helping cells tolerate accumulated proteins.
Another adaptive response is increased reliance on alternative protein disposal pathways such as autophagy. When proteasome function is impaired, cells may redirect damaged proteins to lysosomal degradation systems. This compensatory mechanism helps maintain cellular balance under sustained stress.
Cells may also upregulate chaperone proteins that assist in protein folding, reducing the number of misfolded proteins requiring degradation. Together, these adaptations can reduce the effectiveness of proteasome inhibition over time.
Understanding resistance at a cellular level has led to improved therapeutic strategies that block compensatory pathways and restore sensitivity without increasing toxicity.